Radiation plus immunotherapy for recurrent head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This study tests whether adding an immunotherapy medicine called tislelizumab to radiation can better control recurrent (coming back) head and neck squamous cell cancer. It is aimed at people whose cancer can’t be fully removed by surgery or can’t be safely removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed squamous cell cancer in the head or neck area
- You can do your usual activities fairly well (Karnofsky score of 70 or higher)
- Your cancer has come back after prior “curative” treatment like surgery and/or chemoradiation, and previous radiation plans can be checked
- Your tumor can be measured or described on CT or MRI scans
- You are able to use effective birth control during the study and for up to 180 days after the last dose (and pregnancy testing is negative if you can become pregnant)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (tirelizumab) with two chemotherapy drugs before surgery for head and neck cancer that has spread to lymph nodes. The goal is to shrink the tumor and improve treatment outcomes.
This trial studies whether adding a checkpoint immunotherapy (tislelizumab) and a cancer pill (pamiparib) to radiation can better treat cancer that has come back in the head and neck. It’s for adults with previously treated, HPV-positive oropharynx tumors, usually without widespread spread.
This Phase 2 study tests whether tislelizumab (an immunotherapy) combined with chemotherapy works better for locally advanced head and neck squamous cell cancer. It aims to improve cancer control when the tumor is large and has not spread to distant organs.
This trial tests combining the immunotherapy drug tislelizumab with radiation therapy for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see if this combination helps control the cancer better than standard treatments.
This trial tests whether giving the immunotherapy drug tislelizumab with chemotherapy before surgery can help people with advanced head and neck cancer. The goal is to shrink the tumor enough to remove it completely during surgery.
This trial tests a combination of re-radiation and chemotherapy with the immunotherapy drug pembrolizumab for people whose head and neck cancer has come back after earlier treatment. It compares this approach to standard immunotherapy or chemo-immunotherapy, and may offer a new option for patients whose cancer has a specific marker (PD-L1).
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.